Consensus Cross Country Healthcare, Inc.

Equities

CCRN

US2274831047

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
14.5 USD +1.61% Intraday chart for Cross Country Healthcare, Inc. -0.48% -35.95%

Evolution of the average Target Price on Cross Country Healthcare, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3ed31f83f4bb9bb5a1cc3b626bdb1f.Hbtgndm30hu3p3jQfK86ra2lUJiaLkNaGcrwiHhouE0.Xooo87HomH3-nznlFdps_5vOGs-oQA8Da_qH1wED7D1x_SPOsvKoLebIFw~ad8786fdc81eba81832dd25d220ef13b
Barrington Cuts Price Target on Cross Country Healthcare to $21 From $24, Maintains Outperform Rating MT
Barrington Cuts Price Target on Cross Country Healthcare to $24 From $26, Keeps Outperform Rating MT
UBS Adjusts Cross Country Healthcare Price Target to $19 From $22, Maintains Neutral Rating MT
Truist Adjusts Cross Country Healthcare's Price Target to $16 From $22, Keeps Hold Rating MT
JMP Securities Initiates Cross Country Healthcare With Market Perform Rating MT
UBS Initiates Coverage on Cross Country Healthcare With Neutral Rating, $22 Price Target MT
Barrington Cuts Price Target on Cross Country Healthcare to $26 From $29, Keeps Outperform Rating MT
Jefferies Downgrades Cross Country Healthcare to Hold From Buy, Adjusts Price Target to $21 From $32 MT
Barrington Cuts Price Target on Cross Country Healthcare to $29 From $35 Amid Reduction in Estimates, Keeps at Outperform MT
Credit Suisse Adjusts Cross Country Healthcare's Price Target to $26 From $27, Keeps Neutral Rating MT
William Blair Initiates Cross Country Healthcare at Outperform Rating MT
Barrington Research Cuts Cross Country Healthcare's Price Target to $35 From $42, Maintains Outperform Rating MT
Credit Suisse Lowers Cross Country Healthcare's Price Target to $27 From $32, Keeps Neutral Rating MT
Truist Securities Adjusts Cross Country Healthcare Price Target to $25 From $38, Maintains Hold Rating MT
Loop Capital Initiates Cross Country Healthcare at Buy Rating With $30 Price Target MT
Barrington Trims Price Target on Cross Country Healthcare to $42 From $45, Reiterates Outperform Rating MT
Benchmark Capital Adjusts Cross Country Healthcare Price Target to $40 From $45, Maintains Buy Rating MT
Credit Suisse Lifts Cross Country Healthcare's Price Target to $32 From $31 After Higher-Than-Expected Q4 Results, Keeps Neutral Rating MT
Barrington Raises Price Target on Cross Country Healthcare to $45 From $41, Affirms Outperform Rating MT
Truist Securities Downgrades Cross Country Healthcare to Hold From Buy; Price Target is $36 MT
Barrington Research Raises Price Target for Cross Country Healthcare to $41 From $40, Maintains Outperform Rating MT
Benchmark Adjusts Price Target on Cross Country Healthcare to $42 From $37, Reiterates Buy Rating MT
Barrington Research Lowers Price Target for Cross Country Healthcare to $40 From $44, Maintains Outperform Rating MT
Benchmark Adjusts Price Target on Cross Country Healthcare to $37 From $42, Reiterates Buy Rating MT
Credit Suisse Adjusts Cross Country Healthcare's PT to $26 from $28, Says Current Market Conditions Hurting Valuations Across Board; Keeps Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
14.5 USD
Average target price
18.17 USD
Spread / Average Target
+25.29%
High Price Target
21 USD
Spread / Highest target
+44.83%
Low Price Target
16 USD
Spread / Lowest Target
+10.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cross Country Healthcare, Inc.

Barrington Research
UBS
Truist Securities
JMP Securities
Jefferies & Co.
Credit Suisse
William Blair & Co.
Loop Capital
Benchmark Company
Benchmark Capital
BofA Securities
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
  1. Stock Market
  2. Equities
  3. CCRN Stock
  4. Consensus Cross Country Healthcare, Inc.